Cansino OTC Stock Performance

CASBF
 Stock
  

USD 14.61  0.47  3.12%   

Cansino Biologics holds a performance score of 12 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.3262, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Cansino's beta means in this case. As returns on the market increase, returns on owning Cansino Biologics are expected to decrease at a much lower rate. During the bear market, Cansino Biologics is likely to outperform the market. Although it is vital to follow Cansino Biologics historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. Our philosophy towards foreseeing future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Cansino Biologics expected return of 1.28 will be sustainable into the future, we have found twenty-one different technical indicators, which can help you to check if the expected returns are sustainable. Use Cansino Biologics maximum drawdown, and the relationship between the information ratio and downside variance to analyze future returns on Cansino Biologics.
  
Cansino Performance
12 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Cansino Biologics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak fundamental drivers, Cansino Biologics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more

Cansino Price Channel

Quick Ratio2.44
Fifty Two Week Low5.33
Fifty Two Week High26.00
Trailing Annual Dividend Yield6.72%

Cansino Biologics Relative Risk vs. Return Landscape

If you would invest  770.00  in Cansino Biologics on August 28, 2022 and sell it today you would earn a total of  691.00  from holding Cansino Biologics or generate 89.74% return on investment over 90 days. Cansino Biologics is currently producing 1.2766% returns and takes up 7.5328% volatility of returns over 90 trading days. Put another way, 65% of traded otc stocks are less volatile than Cansino, and 76% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Daily Expected Return (%)  
       Risk (%)  
Assuming the 90 days horizon Cansino Biologics is expected to generate 5.48 times more return on investment than the market. However, the company is 5.48 times more volatile than its market benchmark. It trades about 0.17 of its potential returns per unit of risk. The DOW is currently generating roughly 0.08 per unit of risk.

Cansino Biologics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Cansino Biologics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Cansino Biologics, and traders can use it to determine the average amount a Cansino Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.1695

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small ReturnsCASBF
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative Returns
Estimated Market Risk
 7.53
  actual daily
 
 65 %
of total potential
 
6565
Expected Return
 1.28
  actual daily
 
 25 %
of total potential
 
2525
Risk-Adjusted Return
 0.17
  actual daily
 
 12 %
of total potential
 
1212
Based on monthly moving average Cansino Biologics is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cansino Biologics by adding it to a well-diversified portfolio.

About Cansino Biologics Performance

To evaluate Cansino Biologics OTC Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Cansino Biologics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Cansino OTC Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Cansino Biologics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Cansino's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the Peoples Republic of China. Cansino Biologics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 1946 people.

Things to note about Cansino Biologics

Checking the ongoing alerts about Cansino Biologics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Cansino Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Cansino Biologics Alerts

Equity Alerts and Improvement Suggestions

Cansino Biologics is way too risky over 90 days horizon
Cansino Biologics appears to be risky and price may revert if volatility continues
Cansino Biologics has high likelihood to experience some financial distress in the next 2 years
Cansino Biologics has accumulated about 6.42 B in cash with (586.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 26.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 27.0% of the company shares are held by company insiders
Latest headline from news.google.com: China Equities Lower As Dynamic Zero COVID Is Tested - Forbes
Continue to Trending Equities. Note that the Cansino Biologics information on this page should be used as a complementary analysis to other Cansino Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Cansino OTC Stock analysis

When running Cansino Biologics price analysis, check to measure Cansino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cansino Biologics is operating at the current time. Most of Cansino Biologics' value examination focuses on studying past and present price action to predict the probability of Cansino Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cansino Biologics' price. Additionally, you may evaluate how the addition of Cansino Biologics to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Please note, there is a significant difference between Cansino Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cansino Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cansino Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.